| abstract |
The present invention relates to a proteomic-to-genomic approach that allows in silico validation of biomarkers and drug targets. Biomarkers with high prognostic value in predicting populations of cancer patients that may benefit from mitochondrial biogenesis inhibitory therapy can be identified in this approach. The invention also relates to methods of identifying candidates for mitochondrial therapy, and in particular inhibiting mitochondrial biogenesis therapy. The invention also relates to diagnostic kits comprising reagents for determining transcription products or probes with high prognostic value. In addition, inhibitors of mitochondrial biogenesis can be used as anticancer agents for various oncogenic stimuli, including for example c-MYC and H-Ras oncogenes, as well as environmental stimuli such as, for example, rotenone. |